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Integrated transcriptional profiling 
and genomic analyses reveal RPN2 and HMGB1 
as promising biomarkers in colorectal cancer
Jialing Zhang1,2,3, Bin Yan4, Stephan Stanislaw Späth5, Hu Qun6, Shaleeka Cornelius3, Daogang Guan7, 
Jiaofang Shao8, Koichi Hagiwara9, Carter Van Waes3, Zhong Chen3*, Xiulan Su2* and Yongyi Bi1*
Abstract 
Colorectal cancer (CRC) is a heterogeneous disease that is associated with a gradual accumulation of genetic and 
epigenetic alterations. Among all CRC stages, stage II tumors are highly heterogeneous with a high relapse rate 
in about 20–25 % of stage II CRC patients following surgery. Thus, a comprehensive analysis of gene signatures to 
identify aggressive and metastatic phenotypes in stage II CRC is desired for a more accurate disease classification and 
outcome prediction. By utilizing a Cancer Array, containing 440 oncogenes and tumor suppressors to profile mRNA 
expression, we identified a larger number of differentially expressed genes in poorly differentiated stage II colorec-
tal adenocarcinoma tissues, compared to their matched normal tissues. Ontology and Ingenuity Pathway Analysis 
(IPA) indicated that these genes are involved in functional mechanisms associated with several transcription factors. 
Genomic alterations of these genes were also investigated through The Cancer Genome Atlas (TCGA) database, utiliz-
ing 195 published CRC specimens. The percentage of genomic alterations in these genes was ranked based on their 
mRNA expression, copy number variations and mutations. This data was further combined with published microarray 
studies from a large set of CRC tumors classified based on prognostic features. This led to the identification of eight 
candidate genes including RPN2, HMGB1, AARS, IGFBP3, STAT1, HYOU1, NQO1 and PEA15 that were associated with 
the progressive phenotype. In particular, RPN2 and HMGB1 displayed a higher genomic alteration frequency in CRC, 
compared to eight other major solid cancers. Immunohistochemistry was performed on additional 78 stage I–IV CRC 
samples, where RPN2 protein immunostaining exhibited a significant association with stage III/IV tumors, distant 
metastasis, and poor differentiation, indicating that RPN2 expression is associated with poor prognosis. Further, our 
study revealed significant transcriptional regulatory mechanisms, networks and gene signatures, underlying CRC 
malignant progression and phenotype warranting future clinical investigations.
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Background
Colorectal cancer (CRC) is the third most common can-
cer worldwide [1]. TNM staging is a standard pathology 
classification used for treatment strategy and outcome 
prediction, especially for most stage-I, -III, and -IV 
CRC patients. In the clinical setting, approximately 90 % 
of localized stage I CRC patients are cured by surgi-
cal removal of the tumor burden, so the prognosis and 
treatment plan for stage I CRC patients has been stand-
ardized [2, 3]. However, stage II CRC is highly heteroge-
neous, with 20–25 % of patients exhibiting recurrence or 
relapsed disease following surgery. The 5-year overall-
survival of patients with stage II tumors ranges from 58 
to 85 % [4–6]. Although a wide variety of potential clini-
cal and pathological risk factors have been examined 
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for improved outcome prediction, such as T4 lesions, 
poorly differentiated histology or intestinal obstruction 
[7], the molecular mechanisms underlining the hetero-
geneous characteristics of stage II CRC are still not well 
established. In fact, previous publications indicated that 
clinical outcome prediction and treatment of stage II 
CRC remains controversial, with a necessity for a better 
molecular classification utilizing gene signatures and bio-
markers, in order to complement TNM staging [8–10].
Over the past few years, there has been a significant 
progress in identifying distinct molecular signatures to 
better define CRC subsets. The biological and clinical 
significance of overexpressed oncogenes (i.e. EGFR and 
MYC), and functional loss of tumor suppressor genes (i.e. 
TP53 and APC) have been well characterized [11–15]. 
Better understanding of the oncogenes and related sign-
aling pathways have led to successful CRC therapies, 
especially in targeting the EGFR-RAS-MAPK signaling 
pathway [16, 17]. Further discoveries on TP53 and APC 
have been utilized to predict poor CRC prognosis, with 
the presence of defective of APC expression or point 
mutations in TP53 [18]. However, these gene signatures 
have not been successfully utilized as biomarkers to clas-
sify the heterogeneous stage II CRC for diagnosis and 
treatment. More comprehensive gene signatures and 
signaling transduction pathways related to stage II CRC 
are needed to understand the disease progression and for 
an improved prognosis, as well as treatment.
Recent development of high throughput technologies, 
such as gene expression profiling and genomic sequenc-
ing analysis, enabled us to identify comprehensive cancer 
gene signatures and related signaling pathways, based on 
the genetic and expression alterations in multiple can-
cers [19, 20]. Previously published gene signatures using 
gene profiling, RT-PCR, or sequencing technologies 
varied considerably in terms of their gene composition, 
with little gene overlap [21]. The lack of concordant gene 
signatures could be related to several issues, including 
differences: (1) in technological platforms, such as micro-
array, RT-PCR or sequencing technologies; (2) different 
sample types selected for analysis, and (3) the different 
analytical tools used to generate the gene signatures [22]. 
Hence, an integrative approach combining the informa-
tion derived from different technological platforms, sum-
marizing different categories of genetic and expression 
alterations from a large number of samples, may more 
accurately identify the associations of clinical phenotypes 
with genetic and expression alterations.
In the current study, we performed an integrated data 
analysis, combining gene expression profiles from our 
collected paired stage II CRC patient’s samples, with 
genomic alteration data of 195 CRC samples, previ-
ously published by the Cancer Genome Atlas (TCGA) 
project, along with extracted results from more than 
50 previously published microarray studies. This inte-
grated approach has identified eight gene candidates, 
significantly associated with a progressive CRC pheno-
type. Among these genes, a significantly higher altera-
tion profile for Ribophorin II (RPN2) and High-mobility 
group protein B1 (HMGB1) was observed in CRC tumors, 
compared to other eight major human solid cancer types, 
currently available in the TCGA database. Immunohisto-
chemistry was performed on 78 clinical stage I–IV CRC 
samples, where RPN2 exhibited a significant association 
with distant metastasis and poor differentiation. These 
gene signatures expand the current CRC biomarker pools 
for tumor progression and CRC outcome prediction. Fur-
ther, these gene signatures warrant future validation as 
potential biomarkers in large clinical trials.
Results
Identification of gene expression signatures, related 
pathways and upstream regulators
To investigate important gene signatures in stage II CRC 
tissues with implications in aggressive malignant phe-
notypes, we utilized a cancer-specific array, contain-
ing known cancer related gene probes (N  =  440) for 
mRNA expression profiling. A total of 92 genes, exhib-
iting at least 1.5-fold difference with p < 0.05 in mRNA 
level between tumor and normal samples were identified 
(Additional file  1: Table S1). Unsupervised hierarchical 
clustering algorithm was used to classify sub-populations 
based on the list of differentially expressed genes. As 
expected, tumor and normal samples were clearly sepa-
rated into two subgroups (Fig. 1a). We further identified 
two characteristic clusters, including an over-expressed 
gene cluster A and an under-expressed gene cluster B in 
the tumor subgroup (Fig. 1b, c).
To investigate their functional relevance, we anno-
tated differentially expressed genes in Fig. 1 according to 
Gene Ontology (GO) biological processes, by using the 
DAVID software. We observed significant enrichment 
in apoptosis, phosphorylation, cell proliferation, protein 
kinase cascade, colorectal cancer metastasis and intracel-
lular signaling cascade in stage II CRC (Additional file 1: 
Table S2a). We further applied IPA (Ingenuity Pathway 
Analysis) to identify enriched pathways and unveil the 
functional relevance of our differentially expressed genes 
in stage II CRC. Using this approach, six enriched sub-
networks were hence identified. They were associated 
with NFKB, AP1, STAT3, TP53, HSP90 and CTNNB1 
signaling pathways (Additional file  2: Figure S1). Fur-
thermore, utilizing the IPA tool, we also investigated 
upstream regulatory molecules that are responsible for 
identified pathways and altered gene expression in stage 
II CRC. As shown in Additional file  1: Table S2b, three 
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top transcription regulators TP53, TP63 and TP73 were 
significantly enriched in stage II CRC. In addition, sev-
eral transcription factors and oncogenes ranked top on 
the list, such as NFKB, AP1, STAT3 and MYC, as well as 
other regulators (i.e. E2F1, HIF1A and ANR). This data 
suggests that aberrant regulation of these TFs (NFKB, 
AP1, STAT3, TP53, TP63 and MYC) could potentially 
influence the stage II CRC progression.
Transcriptional regulatory gene network in CRC
To test the hypothesis on how upstream oncogenic and 
tumor suppressor TFs regulate gene expression in stage 
II CRC, we applied a previously developed bioinformat-
ics model [24] able to predict these TFs regulation of 
their target genes. As shown in Additional file  1: Table 
S1, we generated a list of putative targets for the seven 
TFs, including NFKB1, RelA, TP53, TP63, STAT3, MYC 
and AP1. About 35–40 % of NFKB1 or TP53 targets were 
previously validated by experimental data (Additional 
file  1: Table S1). There were twenty-nine NFKB1 tar-
geted genes, consisting of both predicted and validated 
gene candidates, as well as eight unique NFKB1 target 
genes, including RPN2 and HMGB1 (Additional file  1: 
Table S1). In addition, there were many genes under the 
regulation of multiple TFs (Additional file  1: Table S1). 
Subsequently, we constructed a transcriptional regula-
tory gene network, presented in Fig.  2. We predicated 
ten genes being co-targeted by all of the seven TFs, 
including under-expressed (BAX, CDKN1A, CDKN2B, 
LDHA, MDM2, SLC16A1, WEE1) and over-expressed 
(HSP90AB, NQO1 as well as PTMA) genes, respectively. 
These genes are known to be involved in biological pro-
cesses, such as apoptosis, cell proliferation, and cell cycle. 
Our data suggests that the interaction of these seven TFs 
may participate alone or co-regulate the signaling path-
ways, associated with the progression of stage II CRC. 
Genomic and expression alterations of identified 
CRC‑related genes in the TCGA database
To identify the genomic alterations for the differentially 
expressed genes discovered in this project, we took the 
advantage of the TCGA database, containing recently 
published large mRNA expression and genomic altera-
tion data, derived from 195 stage I–IV CRC patients [20]. 
We analyzed 92 differentially expressed genes identified in 
our study, using the TCGA database and determined that 
a total of 24 genes (22 over- and 2 under-expressed genes), 
exhibited consistent expression patterns with the TCGA 
Fig. 1 Identification of CRC gene signatures using global expression profiles. Microarray analysis was performed using stage II CRC cancer speci-
mens (T1-4), compared to matched mucosal tissue samples (N1-4). a Unsupervised hierarchical clustering of differentially expressed genes was 
used to identify differentially expressed genes (fold change 1.5, p < 0.05). Over-expressed and under-expressed genes are indicated by red and 
green colour. The expression level is proportional to colour brightness. Black bars on the left indicate gene clusters A and B, respectively. An expanded 
view of cluster A (over-expressed genes, b), or cluster B (under-expressed genes, c), with the indicated gene names is shown
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data (Additional file  2: Figure S2). Among the over-
expressed genes, RPN2 was altered most frequently in 87 
out of 195 (37 %) CRC cases at stage II and III, including 
significant gene amplification and mRNA overexpression. 
The second most altered gene was HMGB1 (13 %), which 
exhibited a significantly higher rate of mRNA up-regu-
lation (Fig. 3a; Additional file 2: Figure S3). The remain-
ing 19 over-expressed genes were altered similarly in 195 
CRC cases (5–10 %) and across all stages (Fig. 3a; Addi-
tional file  2: Figure S3a). Alterations of TNK1 included 
mRNA down-regulation or mutations in 22 out of 195 
cases (13 %) across all tumor stages (Additional file 2: Fig-
ure S3). We further examined if copy number variations 
(CNVs) are associated with mRNA expression for the 24 
genes, identified in the TCGA. The mRNA expression 
of 14 out of these 24 genes correlated significantly with 
CNVs (Fig. 3b). In addition, ≥25 % recurrent CNVs were 
observed as gains on chromosomes 20q, 13q, 6q, 16q, 
10q, 11q, 12q, 14q, and 1q, as well as losses at 17p and 
1p, respectively (Fig. 3b). Remarkably, RPN2 and HMGB1 
had a higher percentage of CNV in these cases, including 
gains (RPN2 and HMGB1) and amplifications (RPN2, 
Fig. 3b). 
Identification of CRC‑specific gene signatures 
across multiple data sets
Previous evaluation of 29 microarray studies, utilizing 
CRC tumor specimens, has identified 31 gene signatures 
with prognosis significance [31]. Out of these 31 genes, 
28 were overlapping with our identified differentially 
expressed genes from our microarray data, of which 8 
genes (AARS, PEA15, NQO1, STAT1, IGFBP3, HYOU1, 
HMGB1 and IGF2R) were also matched genes, previ-
ously verified in the TCGA dataset (Table 1; Fig. 3; Addi-
tional file 2: Figure S3). Next, we manually searched for 
the presence of these 28 differentially expressed genes 
in 50 previously published microarray studies that were 
utilizing CRC tissues (Additional file  1: Table  S3). The 
50 published microarray studies were selected based 
on prognosis signature inclusion criteria. Sixteen out of 
these 28 genes were overlapping with the 50 published 
microarray experiments. Further investigation revealed 
Fig. 2 Inferred transcriptional regulatory gene network in CRC. A newly developed computational model was utilized to identify target genes of 
seven cancer-related TFs and to construct gene regulatory networks. The triangular nodes represent corresponding TFs. Circle nodes refer to the 
target genes of TFs. Arrow lines show regulatory relationships from TFs to their target genes. Purple or blue lines stand for TFs that act as tumor sup-
pressor or oncogene, respectively. Red and green nodes refer to over- and under-expressed genes, respectively
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that 10 out of these 16 genes (RPN2, AARS, PEA15, 
NQO1, AKT1, STAT1, IGFBP3, HYOU1, HMGB1 and 
IGF2R) also matched with the identified genes in the 
TCGA database (Table 1).
Finally, we selected 8 out of the above 10 genes from 
above list (RPN2, HMGB1, AARS, IGFBP3, STAT1, 
HYOU1, NQO1 and PEA15), based on the following 
criteria: (1) previously identified by CRC tumor micro-
array experiments; (2) previously published as a prog-
nosis markers and (3) identified candidate within the 
transcriptional regulation network presented in Fig.  2. 
The genomic alterations of these selected genes appeared 
to be more evident in stage II, compared to stage I CRC 
tumors, as observed in the TCGA database (Fig.  4a). 
Furthermore, we analyzed these eight genes for altera-
tion frequency in nine major solid cancer types, available 
in the TCGA database. A significantly higher alteration 
frequency for RPN2 and HMGB1 genes was observed 
in CRC tumors, when compared with other tumors 
(Fig. 4b).
Association of RPN2, HMGB1 and NFkB1 protein 
expression with CRC clinic‑pathological features
Based on our observations, where a higher percentage 
of CRC cases exhibited an association between genetic 
alterations and expression profiles in RPN2 and HMGB1, 
as well as NFkB1, a common transcriptional regulator 
of both genes, we performed immunohistochemistry to 
validate RPN2, HMGB1 and NFkB1 protein expression in 
a cohort of additional 78 CRC specimens (Fig. 5). A total 
of 29.5  % of stage I/II and 51.4  % of stage III/IV speci-
mens were positive for cytoplasmic RPN2, with a signifi-
cant association between tumor stages (p  =  0.047). In 
addition, RPN2 staining was also strongly associated with 
distant metastasis (p  =  0.0007) and histological differ-
entiation (p = 0.015), but not with gender, age or tumor 
location (Fig.  5a, b). Characteristic cytoplasmic and 
nuclear staining was observed for NFkB1 in the major-
ity of tumor specimens (stage I–IV). However, cases 
with positive staining were highest in stage III/IV tumors 
but barely reached statistical significance (p  =  0.055, 
Fig.  5a, b). No significant association of NFkB1 protein 
expression was observed for distant metastasis or other 
clinic-pathological features (Fig.  5b). In addition,  ~90  % 
of all examined CRC tumor samples exhibited HMGB1 
immuno-reactivity, however no difference association 
with clinicopathological features was observed (Fig. 5b).
Discussion
In this study, we performed an integrated data analysis 
combining differentially expressed genes from microar-
ray (Fig.  1), with published literature (Additional file  1: 
Table S3) and available genomic, as well as expression 
datasets from TCGA (Figs. 2, 4). The integrated analysis 
Table 1 Comparison of differentially expressed genes with published CRC microarray studies
a The fold changes of differential gene expression between Stage II CRC tumor and normal tissues were extracted from the microarray data presented in Fig. 1
b Prognosis gene signatures were extracted from the publication of Sanz-Pamplona et al., which surveyed 29 microarray studies with patient’s data of recurrence, 
metastasis and survival [25]
c Additional microarray data from 50 previous publications was extracted from CRC tumor and metastatic specimens (Additional file 1: Table S3). The indicated 
number stands for tumor specimens with increased gene expression
d Refers to genes that are involved in transcriptional regulation (Fig. 3; Additional file 1: Table S1) and an overlapping with TCGA data (Additional file 2: Figure S2)
Gene symbol Fold changea Tumors with prognosis  
gene signaturesb
Tumors from other 
microarraysc
TIMP1 8.34 232 52
AARSd 4.48 30
PEA15d 4.23 215 22
CD59 1.61 232
IFITM1 3.03 106
HMGB1d 2.07 215 496
RPN2d 1.91 15
IGF2R 1.75 215 107
IGFBP3d 2.29 232 706
NPM1 2.60 87 679
NQO1d 3.77 55 200
TGFB1 2.35 531
AKT1 3.33 43
HYOU1d 2.16 30
STAT1d 2.83 215 30
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Fig. 3 Evaluation of genomic alterations in TCGA CRC dataset. a Genomic alterations, including copy number variations (CNVs), mutations and 
gene expression of each gene candidate were extracted from the TCGA colorectal cancer (CRC) database. The X- and Y-axis represent genomic 
alterations and case number, respectively. b Variations of mRNA expression versus CNVs and chromosomal locations for individual gene candidates 
are shown. CNV categories include homozygous deletions (Homodel), heterozygous deletions (Hetloss), diploid, gain and amplification (Amp). 
mRNA was expressed as 25th, 50th, and 75th percentile and whiskers represent minimal and maximal values, excluding the outliers. Red circle indi-
cates missense mutations
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identified novel gene signatures in stage II CRC tumors, 
with strong implications for late stage aggressive and 
metastatic phenotypes (Table  1; Fig.  5). Bioinformat-
ics analysis indicated that these genes were regulated by 
seven TFs, including NFKB1, RelA, TP53, TP63, STAT3, 
MYC and AP1 (Fig.  3), and further enriched in NFKB, 
AP1, STAT3, TP53, HSP90 and CTNNB1 pathways, 
known to be important regulators for cell proliferation, 
cell cycle, apoptosis, and intracellular signaling (Addi-
tional file  1: Table S1; Additional file  2: Figure S1). Fur-
thermore, integrated evaluation of large published CRC 
datasets from TCGA identified eight candidate genes 
that were associated with the progressive phenotype of 
CRC (Table  1; Fig.  4a). A significantly higher alteration 
frequency for RPN2 and HMGB1 was also observed in 
CRC tumors, compared to other eight common solid 
tumor types. Finally, immunohistochemistry of RPN2, 
HMGB1 and NFkB1, revealed a significant association 
of RPN2 with CRC stage, metastasis and differentiation, 
in a cohort of additional CRC samples (Fig. 5). Our data 
revealed an association of important gene signatures with 
aggressive stage II CRC and their underlining molecular 
regulatory mechanisms.
Among our differentially expressed gene list, we 
observed several overexpressed genes being tightly 
regulated by several critical TFs that control cell prolif-
eration, survival and inflammation [32–34]. Using IPA 
analysis, to identify upstream regulators for the differ-
entially expressed genes in stage II CRC samples used in 
this study, we observed a strong enrichment for tumor 
suppressor TP53 family members and oncogenic TFs 
(i.e.NFKB, AP1 and MYC) that either individually or 
combined regulate gene expression through shared or 
unique target genes (Fig.  2; Additional file  1: Table S1). 
Fig. 4 Identification of CRC-specific gene signatures across most common solid tumors. a Case numbers with genomic alterations for each gene 
candidate, identified in stage I/II colorectal cancer from the TCGA dataset. b The frequency of genomic alterations for each gene candidates was 
analyzed across nine different solid cancer types (each with >150 tumor samples) from the TCGA database
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The tumor suppressor TP53 family members and onco-
genic TFs (NFKB1, AP1 and MYC) are thought to play 
a crucial role in controlling CRC progression, consistent 
with the observed results in the published TCGA report 
[20]. Our data suggested an existing strong link between 
the regulatory programs of these TFs in CRC. In par-
ticular, this study unveiled several potentially unique tar-
get genes for each TF, such as RPN2 and HMGB1 being 
Fig. 5 Association of RPN2, NFkB1 and HMGB1 protein expression with clinicopathological features in a cohort of CRC. a Immunohistochemical 
analysis of RPN2, HMGB1 and NFkB1 protein expression was performed in a cohort of additional 78 CRC specimens. H&E refers to Hematoxylin and 
Eosin staining. Microscope images were taken at either ×100 or ×400 magnifications. The low-scale bar represents 200 μm and high-scale bar corre-
sponds to 50 μm. b Correlation analysis of RPN2, NFkB1 and HMGB1 expression by gender, age, stages, metastasis, tumor location, and histological 
differentiation in 78 CRC samples. The cases with metastasis were divided into lymph node only and distant metastasis. *Corresponds to a p value 
<0.05 (Fisher’s exact test)
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targeted by NFKB1. These findings are consistent with 
previous studies of these important TFs in carcinogen-
esis [35–37]. Our experimental data from microarray is 
supported by both computational analysis and literature 
searches, where differentially expressed gene signatures 
are shown to promote the malignant CRC process.
Additional support for our experimental data comes 
from the analysis of gene signature expression profiles 
across 195 CRC samples that are associated with differ-
ent CRC stages from the TCGA database (Additional 
file 2: Figure S2). We found that about 55 % of identified 
over-expressed genes from our cancer array did overlap 
with published TCGA data. Interestingly, several genes 
exhibited recurrent CNVs (frequency  >  25  %), which 
directly modulate their mRNA expression (Fig.  3b), 
hence providing a genetic mechanism for gene expres-
sion, showing consistency with previous reports [38, 
39]. These findings highlight our observation that this 
subset of overexpressed genes may play a critical role 
in genomic instability, which is significantly associated 
with progressive CRC phenotypes. We further examined 
gene signatures with a prognostic CRC marker potential 
and by utilizing an integrated analysis approaches, we 
have identified eight gene candidates, including RPN2, 
HMGB1, AARS, IGFBP3, STAT1, HYOU1, NQO1 and 
PEA15. Among this list, six out of eight genes have been 
previously implicated in deregulation of gene expres-
sion and associated with the prognosis of CRC and other 
cancer types [40–43]. Only RPN2 and AARS were novel 
genes, with no previous publication describing their 
functional contribution to CRC. The genetic alteration 
and expression profiles for this eight candidate genes 
were compared across different cancer types. Only 
RPN2- and HMGB1-genes were found to be most altered 
in CRC (Fig. 4b), further supporting their biological sig-
nificance in CRC pathogenesis. We used a cohort of 78 
independent CRC specimens (stages I–IV) to validate 
RPN2, HMGB1 and NFkB1 protein expression and their 
association with several clinic-pathological features. We 
observed that only RPN2 expression was significantly 
associated with tumor stage, histological differentiation 
and distant metastasis (Fig.  5). HMGB1 was positively 
expressed in 90 % of cells in all tumor stages and across 
our selected CRC samples. HMGB1 has been previously 
implicated in CRC with controversial roles in cancer 
immunity and metastasis [44–48]. Although, it was not 
significantly associated with clinic-pathological features 
in our CRC samples (Fig.  5b), we still observed a con-
sistent mRNA and protein over-expression of HMGB1 
(Figs.  1, 5), as well as significant correlation between 
mRNA and CNV gains (Fig.  3b). Our data suggest that 
these gene markers can be identified in CRC samples, as 
early as stage II, but are not solely stage II specific. The 
consistent overexpression of these gene markers further 
supports their functional importance as oncogenes in 
tumor progression.
Our bioinformatics analysis suggests that HMGB1 
and RPN2 are both targeted by an oncogenic TF, namely 
NFkB1 (Fig.  2). In fact, aberrant expression of NFkB1 
expression was also observed in about 29.7  % of stage 
III/IV CRC cases (Fig.  5), which is consistent with pre-
viously published findings [43]. The RPN2 gene, located 
on chromosome 20q13, encodes a proteasome scaf-
folding protein that inhibits Bcl-mediated apoptosis 
and stabilizes mutated p53 protein expression through 
inactivation of GSK3β in breast cancer [49, 50]. Over-
expression of RPN2 in stage II CRC was also reported by 
another microarray that focused on CRC tumor metas-
tasis (Table  1), supporting its implication beyond early 
staged tumors. In TCGA CRC dataset, RPN2 up-regu-
lation was observed in 65 out of 195 CRC cases (37  %) 
and was significantly associated with copy number gain 
(Fig. 3). This is consistent with previous findings, where 
>65  % of CRC cases have shown gains on chromosome 
and a strong association with liver metastasis and poor 
outcome [51–53]. In addition, we examined RPN2- and 
HMGB1 alteration profiles in 195 CRC staged patients, 
available in the TCGA database, by ranking them accord-
ing to their alteration rates (Additional file 2: Figure S2). 
Further evaluation revealed a slightly longer survival of 
patients without RPN2 alteration, but that did not reach 
statistical significance (p  =  0.38, data not shown). This 
survival data may be valid, because the marker was not 
originally identified as a predictor for CRC survival in all 
stage cancers. It will be interesting to complement the 
genetic alteration and differential expression profiles of 
these molecules as biomarkers in future clinical trials for 
stage II CRC patients.
Furthermore, the importance of RPN2 in tumor prog-
nosis and therapeutic implications has been documented 
in other solid cancers, including esophageal squamous 
cell carcinoma [54, 55], osteosarcoma [56, 57] and breast 
cancer [50]. We observed that RPN2 is also highly altered 
in head and neck squamous cell carcinoma (HNSCC), as 
well as lung squamous cell carcinoma (Fig. 4b), consist-
ent with previously published studies [55, 58]. In various 
human malignancies, silencing of RPN2 was associated 
with increased apoptosis, reduced tumor growth and 
increased sensitivity of tumor cells to docetaxel response 
[49, 54]. The value of RPN2, both as a prognostic marker 
and as a therapeutic target is suggested for future valida-
tion. In this manuscript, we have shown that CRC cases 
with RPN2 staining were significantly higher in stage 
III/IV, in distant metastatic, and poorly differentiated 
tumors, indicating that its expression is associated with 
worse prognosis. In addition, NFkB1 protein expression 
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was also associated with distant metastasis. Our data 
presents experimental evidence that RPN2 protein 
expression could serve as a potential biomarker to pre-
dict metastasis and worse prognosis. However, due to the 
lack of patient survival and outcome data in the current 
study, these molecules need to be further validated for 
their value as biomarkers in larger clinical trials.
Conclusions
In this manuscript, by utilizing mRNA profiling, we 
have identified a panel of differentially expressed gene 
signatures in stage II colorectal adenocarcinoma tis-
sues. Through integrated analyses of the transcriptional 
regulation, The Cancer Genome Atlas database, and 50 
published microarray studies of colorectal cancer speci-
mens, we have identified eight candidate genes that 
are significantly associated with the aggressive pheno-
type, including RPN2, HMGB1, AARS, IGFBP3, STAT1, 
HYOU1, NQO1 and PEA15. Among those genes, RPN2 
and HMGB1 displayed higher frequencies of genomic 
alterations in colorectal cancer, compared to other solid 
tumors. Furthermore, RPN2 protein expression evalu-
ated by immunohistochemistry in 78 independent (stage 
I–IV) colorectal cancer tissues, exhibited a significant 
association with stage III/IV tumors, distant metastasis, 
and poor differentiation. Our study identified important 
molecular signatures underlying malignant progres-
sion and phenotype of colorectal cancer, which warrants 
future clinical investigations.
Methods
Patients
This study was approved by the ethical committee 
at Inner Mongolia Medical University and a written 
informed patient consent was obtained. A total of 82 
patients were diagnosed with pathological stages (Addi-
tional file 2: Figure S3) and underwent surgical resection 
for CRC at Inner Mongolia Medical University Hospi-
tal from 2002 to 2006 and were diagnosed with patho-
logical stages. Patients with hereditary syndromes, e.g. 
familial adenomatous polyposis (FAP), Lynch syndrome 
or hereditary nonpolyposis colorectal cancer (HNPCC), 
or inflammatory syndromes were pre-screened and 
excluded from this study. The preoperational chemo-
radiotherapy or chemotherapy could significantly influ-
ence the expression of biomarkers. Hence none of the 
patients used in this study received treatment prior to 
surgery. Tumor staging was performed according to 
TNM classification criteria and guidelines of the Inter-
national Union Against Cancer (UICC) guidelines [23]. 
Histological differentiation was evaluated, as poorly dif-
ferentiated carcinomas are known to have a high-risk 
of recurrence or metastasis. Accordingly, we randomly 
selected 4 poorly differentiated adenocarcinoma (stage 
II) samples with matched adjacent normal mucosa tissues 
and performed microarray analysis. Histological evalu-
ation confirmed the content of tumor- or normal colon 
epithelium cells to be more than 50 % (Additional file 2: 
Figure S1b).
RNA extraction and microarray profiling analysis
Total RNA was isolated from frozen tissue samples and 
extracted using the RNeasy Mini Kit (QIAGEN, Mary-
land, USA) according to manufacturer’s instructions. 
Gene expression was analyzed using Oligo GEArray 
Human Cancer Microarray® (Cat# OHS-802SA, Bio-
sciences, CA, USA), which contains a total of 480 probes 
for 440 genes, encoding for tumor suppressors, onco-
genes, signal transduction molecules, growth factors and 
their corresponding receptors, as well as others asso-
ciated with angiogenesis. Gene expression levels were 
normalized to the beta-actin housekeeping gene. The 
selection criterion of differentially expressed genes was 
based on at least 1.5-fold threshold between the CRC 
tumors and matched normal tissues.
Computational inference of transcription factor target 
genes
We have developed a mathematical model, capable to 
identify target genes of a particular transcription factor 
(TF) and thus to construct a gene network, regulated by 
that TF. By recursively applying this model to the identi-
fied network, multiple networks can be interconnected. 
Moreover, the model is able to infer how likely a gene is 
regulated by a particular TF, which has been successfully 
applied in other cancer datasets [24–28]. In this study, 
this model was applied to the above-obtained CRC differ-
ential gene expression data, in order to investigate target 
genes regulated by seven common cancer-related TFs, 
including NFKB1, RELA, AP1, TP53, TP63, STAT3 and 
MYC.
Genomic alterations from TCGA database
The cancer genome Atlas (TCGA) project has published 
the first “Marker” paper of colon cancer in 2012, which 
included genomic sequencing, epigenetic and mRNA 
expression profiling across 195 human colorectal cancer 
specimens [20]. The data is accessible through the cBio 
Cancer Genomics Portal (http://cbioportal.org) [29], 
a web resource designed for the visualization of oncog-
enomic datasets. Using the differentially expressed gene 
list in our current study, we extracted genomic altera-
tion profiles from 195 CRC specimens, which have been 
published and deposited in the TCGA database. Since 
the first “Marker” paper of colon cancer was published 
[20], there is a constant submission of more colon cancer 
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samples to the TCGA project, for continued generation 
of high throughput experimental data. However, not 
all of these data are complete or have gone through the 
confirmation and validation process, and thus are not 
included in this study.
Immunohistochemical analysis
Thin sections of 10 % formalin-fixed, paraffin-embed-
ded tissue specimens were treated with goat anti-
human RPN2 antibody (sc-12165, Santa Cruz), rabbit 
anti-human HMGB1 antibody (#6893S, Cell Signal-
ing), or rabbit anti-human NFKB1 antibody (sc-1190, 
Santa Cruz), followed by a peroxidase-conjugated 
goat anti-rabbit (sc-2018, Santa Cruz) or rabbit anti-
goat (sc-2023, Santa Cruz) secondary antibody. Color 
was developed using Avidin and Biotin-conjugated 
horseradish peroxidase (ABC reagents) and accord-
ing to standard protocols. The percentage of posi-
tively stained cancer cells was determined under the 
microscope from more than four visual fields (at 400× 
magnification). Specimens were evaluated by two 
independent pathologists and classified into 2 groups: 
negative staining (no cells were intensely stained), and 
positive staining (at least 10  % cells were intensely 
stained) [30].
Statistical analysis
Correlation between gene expression and distinct clin-
icopathologic characteristic was analyzed by the Fisher’s 
exact test. For all statistical analysis, a P value of <0.05 
was considered significant.
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